HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES-  SCLC   - HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 ...

VIENNA, Va., September 10, 2024--CEL-SCI to present new data for Multikine head & neck cancer immunotherapy at the European Society for Medical Oncology 2024 Congress.

TJH is on the MCBS working group for the European Society for Medical Oncology. Q-DT reports grants from Pfizer and consulting fees from Astellas, Bayer, Intuitive Surgical, Janssen, Novartis, and ...

For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, ...

Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer ...

Bowers added that to increase access to the latest drugs, the "cancer system" must be organized in such a way as to ...